Crop Life Science reported a net profit of ₹698.69 lakh for the year ended March 31, 2026, an increase from ₹662.03 lakh in the previous year. Revenue from operations rose to ₹20,717.42 lakh from ₹20,059.00 lakh in FY25. The company's basic and diluted earnings per share stood at ₹4.08 for the year, compared to ₹3.86 in the prior year.

Financial Performance

The total income for the year grew to ₹20,888.52 lakh from ₹20,157.16 lakh in the previous year. Total expenses increased to ₹19,904.37 lakh from ₹19,256.08 lakh. The profit before tax for the year was reported at ₹990.43 lakh, up from ₹900.99 lakh in FY25.

Segment Information

The company operates in two business segments: manufacturing and dealing in pesticides, insecticides, herbicides, fertilizers, and allied products related to research and technical formulations; and trading of agro products. For the consolidated financial statements, the company considered agro chemicals as the only reportable segment as trading activities did not meet the quantitative thresholds prescribed under Ind AS 108.

Consolidated Results

On a consolidated basis, the company reported a net profit of ₹649.49 lakh for the year ended March 31, 2026, compared to ₹560.11 lakh in the previous year. Total revenue from operations for the group stood at ₹20,717.42 lakh. The profit attributable to the owners of the company was ₹663.51 lakh, while non-controlling interest was reported at a loss of ₹14.02 lakh.

Board Approval and Auditor's Report

The Board of Directors approved the audited standalone and consolidated financial statements and results for the half year and year ended March 31, 2026 at its meeting held on May 26, 2026. The statutory auditors, Shah & Shah Chartered Accountants, issued an audit report with an unmodified opinion on the standalone and consolidated financial results.

Crop Life Science Limited has approved an additional Working Capital Term Loan of ₹7.96 crore from HDFC Bank under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0. The Board of Directors sanctioned the borrowing during a meeting held on June 03, 2026, at the company's registered office to bolster its liquidity position.

The approval was part of the agenda discussed at the board meeting, which commenced at 05:00 PM and concluded at 06:00 PM. The decision aligns with the company's strategy to utilize available government-backed credit facilities to strengthen its financial health.

Key Details of the Approval

The resolution passed by the board specifically pertains to the availing of funds under the ECLGS 5.0 framework. This scheme is designed to provide emergency credit support to businesses, aiding in the recovery of economic disruptions.

The disclosure was submitted to the National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rajeshkumar Vrajlal Lunagariya, Managing Director, signed the filing on behalf of the company.